PAION Initiates Phase II Trial With Its Anesthetic/Sedative CNS 7056
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces the commencement of the initial Phase II study with CNS 7056, a new short-acting intravenous anesthetic/sedative. The study will enroll 100 patients undergoing diagnostic endoscopy of the upper gastrointestinal tract.
Related Posts
Tags: 7056, anestheticsedative, initiates, paion, phase, trial
This entry was posted on Friday, April 17th, 2009 at 8:04 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.



